Mannatech: Share Price Staying Strong

Mannatech is fast becoming a robust identity both within the health and wellness industry and on the stock market. The company has made a conscious effort to promote itself as a cutting edge organization, firmly grounded in scientifically validated nutritional products. (http://www.mannacentre.com) So far they seem to be succeeding, although Mannatech's popularity has been met with considerable skepticism from the pharmaceutical drug industry. In fact based on the negative press that Mannatech has received from some of the more conservative sectors of the medical industry, it would be easy to conclude that Mannatech is just another short term boom and bust fad, conjured up by entrepreneurial gamblers. A deeper look at this company soon reveals a far different reality that exudes substance and integrity. In fact Mannatech's rapid but consistent growth both geographically and in unit sales over the past 12 years, has been sufficient to convince the NASDAQ that Mannatech is here to stay. The stock price is hovering at just under $13 which translates into a resounding vote of confidence, within industry that has traditionally been plagued by peddlers of "snake oil". Much of the financial interest has been generated by cumulative sales of the company, which just exceeded $1.5 billion and annual sales numbers that have more than doubled in just two years. The product that forms the core of Mannatech's business is Ambrotose, which has been secured with a range of patents that look certain to keep Mannatech's flagship in tact for many years to come. However, the major "blip" on the radar for this company lies in how its sale will react to the slow down of the US economy. Some are predicting a volatile reaction as consumers may seek to cut luxury items to compensate for the rising cost of living. (http://www.mannatechnews.com) Mannatech on the other hand remain confident that their products are fast becoming a core health product, capable of withstanding considerable financial pressure.